(Q38793981)

English

Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications

scientific article published on 12 November 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

author name string

Katherine H Luepke

1

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Katie J Suda

2

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Helen Boucher

3

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Rene L Russo

4

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Michael W Bonney

5

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Timothy D Hunt

6

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

John F Mohr

7

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

language of work or name

0 references

publication date

12 November 2016

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

37

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

71-84

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

History of infections associated with combat-related injuries

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

The future of antibiotics

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

The true cost of antimicrobial resistance

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

Trends in antimicrobial drug development: implications for the future

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

The FDA reboot of antibiotic development

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

Fix the antibiotics pipeline.

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

Time for a change: addressing R&D and commercialization challenges for antibacterials

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

National trends in prescription drug expenditures and projections for 2016.

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

Antibacterial drug discovery: is it all downhill from here?

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

Improving antimicrobial stewardship: the evolution of programmatic strategies and barriers

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

Outcomes and metrics for antimicrobial stewardship: survey of physicians and pharmacists

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

Public funding of clinical-stage antibiotic development in the United States and European Union

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

A comprehensive regulatory framework to address the unmet need for new antibacterial treatments.

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

Repairing the broken market for antibiotic innovation

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach.

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

Global trends in antimicrobial use in food animals

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010-2011

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

Are physicians' prescribing decisions sensitive to drug prices? Evidence from a free-antibiotics program

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

Free antibiotic and vaccination programmes in community pharmacies of Miami-Dade County, FL, USA.

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013.

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

The effect of cost sharing on the use of antibiotics in ambulatory care: Results from a population-based randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FPHAR.1868

21 January 2018

Identifiers

10.1002/PHAR.1868

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38793981&oldid=1786970206"